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Abstract In Saccharomyces cerevisiae, the first two reactions
of pyrimidine biosynthesis are catalyzed by the multifunctional
protein Ura2 carrying both carbamyl-phosphate synthetase
(CPSase) and aspartate transcarbamylase (ATCase) enzyme
activities. In order to study how UTP regulates both of these
activities mutant strains were constructed: one strain which
expressed the Ura2 protein fused to the green fluorescent protein,
and two strains expressed truncated Ura2 proteins. These strains
exhibited a phenotype associated with a modified regulation of
the pyrimidine pathway. Results presented in this report provide
arguments in favor of a single UTP binding site located on the
CPSase domain, and support a model in which ATCase activity
is inhibited by UTP only when it can interact with the CPSase
domain.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
In Saccharomyces cerevisiae, the ¢rst two steps of pyrimi-
dine biosynthesis are catalyzed by the Ura2 protein. The Ura2
polypeptide chain (2212 aa), encoded by the gene URA2, car-
ries four di¡erent domains, three of which are enzymatically
active: GATase (glutamine amidotransferase), CPSase (car-
bamyl phosphate synthetase) and ATCase (aspartate transcar-
bamylase). Located between CPSase and ATCase, the fourth
domain has no known activity in the Ura2 protein, although
it catalyzes the third reaction of the pathway (dihydroorotase
(DHOase)), in CAD, the mammalian counterpart of Ura2.
This intermediary domain has been called DHOase-like in
Ura2 since its sequence presents homologies with CAD [1].
CPSase synthesizes carbamyl phosphate (CP) from bicarbon-
ate, ATP-Mg and glutamine. ATCase uses CP and aspartate
to synthesize ureido-succinate. Both enzymatic steps are sub-
ject to feedback regulations by UTP which take place at two
levels : repression of URA2 gene transcription, and inhibition
by UTP of both enzymatic activities [2] ; the inhibition of the
¢rst two activities of the pyrimidine pathway is speci¢c for the
yeast enzyme and does not take place in CAD in which only
the CPSase activity is inhibited by UTP [3].
Mutations which a¡ect repression of the URA2 gene have
never been found although they were looked for very carefully
by F. Lacroute’s group; in contrast, mutations which a¡ect
inhibition of Ura2 activities were found to map on the Ura2
gene: they result in a loss of sensitivity towards UTP of either
CPSase, ATCase or both activities. Some of these mutations
have been shown to lead to the excretion of uracil responsible
for a 5-£uorouracil resistant (FUR) phenotype used for
screening such mutant cells [4]. Recently FUR2 point muta-
tions (‘2’ since they are allelic to URA2) have been mapped:
they were shown to be gathered on the Ura2 protein sequence
either on the ATCase domain or on the CPSase domain [5].
These results suggested either a regulation which could de-
pend on two UTP independent regulatory sites, or a regula-
tion based on interactions between domains one of which
would carry the UTP binding site.
The respective contribution of each domain to the mecha-
nism of ATCase inhibition by UTP was investigated in this
work, with the help of di¡erent in vitro URA2 constructions
expressing modi¢ed Ura2 protein: a Ura2 protein fused to a
GFP (green £uorescent protein) domain, and two di¡erent
truncated Ura2 proteins. Results support the fact that a single
UTP binding site is located on the CPSase domain and pro-
vide arguments for a model in which ATCase activity would
be feedback-inhibited only when it can interact with the
CPSase domain.
2. Materials and methods
2.1. Materials
Na[14C]aspartate 200 mCi/mmol and Na[14C]bicarbonate 55 mCi/
mmol were from Amersham SA. Yeast extract, yeast nitrogen base
and peptone were from Difco Laboratories. UTP was from Pharma-
cia, ATP and L-aspartate from Sigma-Aldrich. All other products
were from Prolabo.
2.2. Yeast strains and growth conditions
Two strains derived from FL100 wild type (ATCC 28383) and
W303.1A leu2-3,112 ura3-1 his3-11,15 trp1-1 ade2-1 can 1-100 (R.
Rothstein UMDNJ-New Jersey Medical School, Newark USA) were
used to express recombinant TRP1 vectors carrying the modi¢ed ver-
sions of URA2 : MD 296.16A (K CPA2 ura2v : :HIS3 trp1-1) and MD
293.9A (K cpa2 ura2v : :HIS3 trp1-1). In both strains, the URA2 chro-
mosomal gene was totally deleted by a HIS3 insertion (ura2v : :HIS3)
made according to [6]. Transformed strains were called by the name of
the plasmid preceded by CPA2 or cpa2, depending upon the recipient
strain used, respectively MD 293.16A or MD 293.9A.
Precultures were made in YPD (yeast extract 1%, peptone 2%,
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glucose 2%) supplemented with arginine and uracil 40 mg/l. Precul-
tures of transformed cells only were done in YNB (yeast nitrogen base
0.67 g/l bu¡ered with sodium citrate/citric acid to pH 5.6) supple-
mented with uracil and a mixture of amino acids and bases which
included arginine, uracil and adenine but not tryptophan. Cultures
were made in YNB bu¡ered as above and supplemented as mentioned
in legends. One OD660 unit corresponds to about 2^4U107 haploid
cells/ml.
Plasmid constructions are presented in Fig. 1. Plasmid pRA5N
(p5N) is the reference centromeric plasmid, derived from pNC160
[7], it carries the wild type URA2 gene under its own promoter. Plas-
mid pRA21 (p21) carries a 3P fusion of URA2 with the GFP coding
sequence; this vector was constructed by inserting in the last MscI site
of the URA2-ORF a PCR product which contains the GFP sequence
from Aequorea victoria (mutation pS65T-C1, from Clontech). This
ampli¢cation also introduced a small sequence encoding a 5 amino
acid linker between Ura2p and GFP. Plasmids pRAvCPS or [pvCPS]
and pRAvATC or [pvATC] were both constructed by inverse PCR,
the selected domain sequence being deleted directly on the ¢nal plas-
mid ([8] and publication submitted).
2.3. CPSase and ATCase enzyme activities
CPSase and ATCase enzyme activities were measured by permeabi-
lization as in [9] using conservation bu¡er (Tris-acetate 50 mM, pH
7.4, glycerol 10% v/v, ethylene glycol 30% v/v, EGTA 2 mM, pepsta-
tin 2 WM, PMSF 1 mM). ATCase activity was measured as in [10],
Na[14C]aspartate (about 5U104 dpm/Wmol) being the substrate. Spe-
ci¢c activity was expressed in Wmol of ureido-succinate/h/1010 cells.
CPSase activity was measured as in [10,11] using Na[14C]bicarbonate
(about 7U105 dpm/Wmol). Speci¢c activity was expressed in Wmol of
ureido-succinate/h/1010 cells. Both activities were determined using
three increasing volumes of cell suspension, alternatively determina-
tions were done in triplicate.
3. Results
It should be recalled that in S. cerevisiae, CP is produced
not only by the CPSase-ura (encoded by URA2), but also by
the CPSase of the arginine pathway (CPSase-arg encoded by
genes CPA1 and CPA2) [12]. Thus, if UTP inhibition of AT-
Case can be measured in a CPA2 background, regulation of
the CPSase-ura can only be measured in a cpa2 background
(i.e. deprived of CPSase-arg activity). Typically, a cpa2 URA2
strain (i) grows on YNB minimum medium because its
CPSase-ura provides CP for both uracil and arginine path-
ways (i.e. it does not strictly channel CP to pyrimidine syn-
thesis) ; but (ii) cannot grow when uracil is added to the YNB
medium because the repleted pool of UTP represses URA2
and inhibits CPSase-ura activity, CP synthesis is thus stopped
and arginine is no longer made.
Strain cpa2 [p5N], which carries wild type URA2 under its
own promoter, has been used as a control in this work since it
has been shown to exhibit the same characteristics as de-
scribed above for cpa2 URA2 strains.
A 3P-terminal fusion of URA2 with the GFP sequence and
two partial deletions of URA2 have been constructed; the
corresponding proteins have been analyzed in this study
(Fig. 1).
3.1. The Ura2-GFP fusion protein carries CPSase and
ATCase activities, both less sensitive to UTP
inhibition than the control protein
Cells CPA2 [p21], which express the Ura2-GFP fusion, were
found to grow on minimal medium and to excrete uracil. They
were able to grow in the presence of 10 mM of a toxic analog
of uracil, 5-£uorouracil (5FU), a phenotype called FUR2 (£u-
orouracil resistant), which suggested an active ATCase no
longer regulated by UTP [4]. The ability of cells cpa2 [p21]
to grow on minimal medium (Fig. 2) revealed that CPSase-ura
of the Ura2-GFP fusion protein was enzymatically active;
however, since these cells were able to grow slowly in the
presence of uracil, this CPSase was apparently not regulated
as tightly as the control enzyme. Thus, both activities present
on the fusion protein seemed not to be regulated properly.
Repression and inhibition of CPSase and ATCase activities
expressed in cpa2 [p21] cells were measured as explained and
presented in Table 1. A similar level of repression was found
for both activities in cpa2 [p21] and in cpa2 [p5N] cells,
although speci¢c activities were slightly higher in the latter.
This repression was con¢rmed by quanti¢cation of the URA2
messenger RNA on Northern blots (data not shown). In con-
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Fig. 1. Presentation of the four plasmids used in this study and
which express from p5N, (1) the control Ura2 protein; from p21,
(2) the fusion protein Ura2-GFP; from pvCPS, (3) a truncated
Ura2 protein lacking the CPSase domain; from the pvATC, (4) a
truncated Ura2 protein lacking the ATCase domain.
Table 1
ATCase and CPSase activities measured during exponential phase growth of four strains which express (1) the control Ura2 protein encoded
by p5N, (2) the fusion protein Ura2-GFP encoded by p21, (3) a truncated Ura2 protein lacking the CPSase domain encoded by pvCPS, and
(4) a truncated Ura2 protein lacking the ATCase domain encoded by pvATC
Strain Protein expressed Growth conditions ATCase CPSase
Speci¢c
activity
Inhibition by 2 mM
UTP (%)
Speci¢c
activity
Inhibition by 2 mM
UTP (%)
(1) cpa2 [p5N] Wild type YNB 40 55 2.6 58
YNB+uracil 200 mg/l 14 43 1.0 50
(2) cpa2 [p21] Ura2-GFP YNB 34 3 2.3 13
YNB+uracil 200 mg/l 10 0 1.1 0
(3) cpa2 [pvCPS] DHO-ATC YNB+uracil 200 mg/l 21 0 ^ ^
(4) cpa2 [pvATC] CPS-DHO YNB+uracil 200 mg/l ^ ^ 1.3 0
Both speci¢c activities are expressed in Wmol of ureido-succinate/h/1010 cells. Repression of the URA2 gene was estimated, when possible, by the
ratio between activities measured in cells grown in the presence of 200 mg/l of uracil, and activities of cells grown on minimal medium. Sensitivity of
both activities towards UTP was routinely estimated by the ratio between activities measured in the presence and in the absence of 2 mM UTP in
the assay.
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trast, both activities of the fusion protein exhibited a lower
sensitivity to UTP than the control enzyme. ATCase activity
was poorly inhibited even in the presence of high concentra-
tions of UTP (Fig. 3A): the [UTP]0:5 (concentration of UTP
necessary to inhibit half of the maximum activity) was ap-
proximately an order of magnitude higher for the chimeric
protein (12 mM) than for the wild type enzyme (1 mM).
However, as shown in Fig. 3B, cpa2 [p21] CPSase activity,
which remained insensitive to UTP up to a concentration of
1^2 mM, was ¢nally inhibited to the same extent as the con-
trol enzyme when higher concentrations of UTP were used;
the [UTP]0:5 was about 4 mM for the p21-CPSase, compared
to 2 mM for the control.
3.2. The Ura2 protein deprived of the CPSase domain exhibits
an ATCase totally insensitive to UTP inhibition
In order to determine the role of each domain in the feed-
back inhibition of both activities, two domain-speci¢c dele-
tions were made on URA2 (Fig. 1): a deletion of the ATCase
domain (carried on plasmid pvATC), and a deletion which
will be referred to as vCPS although it overlaps both GATase
and CPSase domains; it is carried by plasmid pvCPS.
cpa2 [pvATC] cells have no ATCase activity. They were
found to grow on minimal medium plus arginine and uracil,
but also in the presence of 200 mg/l uracil alone, suggesting a
CPSase-ura still active but not properly regulated. Measure-
ments of vATC-CPSase activity were made only in cells
grown in the presence of uracil, and, since these cells do not
grow on minimal medium, it was not possible to estimate the
level of repression. Results presented in Table 1 show that
vATC-CPSase has speci¢c activity roughly similar to the con-
trol measured in cells grown in the same conditions; we thus
estimated that the repression level was likely not changed in
the mutant cells cpa2 pvATC. However, this CPSase activity
had lost part of its sensitivity to UTP, and the kinetics of its
inhibition when UTP concentrations increased was found to
be totally di¡erent from the control kinetics: activity de-
creased exponentially while the control followed a sigmoidal
curve (Fig. 3B).
cpa2 [pvCPS] have no CPSase activity at all. As above, it
was not possible to estimate the level of repression in these
cells since they do not grow on minimal medium. vCPSase-
ATCase-speci¢c activity was measured in cells grown in the
presence of uracil, and it was found to be slightly higher than
the control measured in cells grown in the same conditions.
CPA2 [pvCPS] cell growth on minimal medium (Fig. 2)
indicates the presence of a functional ATCase domain, even
in the absence of the whole CPSAse domain; their growth in
the presence of 5FU reveals a FUR2 phenotype associated
with an ATCase insensitive to UTP inhibition, as shown in
Table 1. Actually, ATCase activity appeared to be activated
when UTP concentrations were increased (Fig. 3A); neverthe-
less, this activation was considered not to be speci¢c since
other nucleotides besides UTP ^ such as UMP, CTP and
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Fig. 3. Impact of increasing amount of UTP on the two Ura2 activities. A: Variations of the ATCase activity due to (b) the control Ura2 pro-
tein encoded by p5N; (F) the fusion protein Ura2-GFP encoded by p21; (8) a truncated Ura2 protein lacking the CPSase domain encoded by
pvCPS; (7) ATCase activity of pvCPS assayed in the presence of 2, 5 and 10 mM of ATP, CTP and UMP. (Similar values were found for
all three nucleotides.) B: Variations of CPSase activity due to (b) the control Ura2 protein encoded by p5N; (F) the fusion protein Ura2-GFP
encoded by p21; (R) a truncated Ura2 protein lacking the CPSase domain encoded by pvATC. All plasmids were expressed in a cpa2 ura2v
background; cpa2[p5N] and cpa2[p21] were grown on YNB, cpa2[pvCPS] in YNB supplemented with 200 mg/l uracil and 40 mg/l arginine,
cpa2[pvATC] in YNB supplemented with 200 mg/l uracil.
Fig. 2. Growth curves of the di¡erent mutant strains in comparison
with the control strain in minimal medium plus 200 mg/l uracil
(open symbols) or without uracil (closed symbols). Symbols for the
three strains: cpa2[p5N] (circles); cpa2[p21] (squares); cpa2[vATC]
(triangle).
R. Antonelli et al./FEBS Letters 422 (1998) 170^174172
ATP ^ were found to have a similar inhibitory e¡ect on ATC-
ase activity. Triphosphate compounds could be responsible
for this positive interference, since phosphate ions have been
found to interfere with ATCase activity [13].
4. Discussion
This study was mainly focused on the way inhibition by
UTP of ATCase and CPSase activities takes place in the yeast
multifunctional protein Ura2. Nevertheless, repression by pyr-
imidines of the URA2 gene was also estimated in cpa2 [p5N]
and in cpa2 [p21] strains: speci¢c activities as well as messen-
ger RNA expression were measured in cells grown in the
presence and in the absence of uracil. The level of repression
by pyrimidines was found to be similar to that previously
measured in wild type cells, i.e. about 1.5^3. Repression was
thus considered not to be modi¢ed in the cpa2 [21] strain.
Truncated Ura2 protein-speci¢c activities were measured in
repression conditions only (i.e. in the presence of 200 mg/l
uracil) ; data were found to be similar to (for cpa2 [pvATC]
CPSase), or slightly higher (for cpa2 [pvCPS] ATCase) than,
the control. Repression was thus assumed not to be signi¢-
cantly modi¢ed when truncated Ura2 proteins were ex-
pressed; a conclusion consistent with the fact that, even
when no Ura2 polypeptide is made, a normal level of repres-
sion by pyrimidines of the URA2 promoter has been found by
Potier [14], as well as by us (i.e. the synthesis of the GFP
protein directly fused to the URA2 promoter and expressed
in an ura2 deletion strain was normally repressed by pyrimi-
dines).
Inhibition by UTP of Ura2 ATCase and CPSase activities
was analyzed in a Ura2-GFP fusion protein and in two trun-
cated Ura2 proteins. The two domain-speci¢c deletions cover
either the ATCase or the CPSase coding region but do not
include the intermediary DHOase-like region. Each of the
corresponding truncated Ura2 proteins was found to be active
in the absence of the other domain. However, as proposed
before by Roelants [15], it cannot be excluded that the
DHOase-like region of the polypeptide contributes to the nor-
mal folding of the catalytic domains. Deletion of the ATCase
domain resulted in a CPSase which remained sensitive to
UTP, but less so than the wild type enzyme. This result sug-
gests that the UTP binding site might be located either on the
CPSase domain (as shown for E. coli [16] or CAD CPSase
[17]), or on the DHOase-like region also present on this trun-
cated protein. On the other hand, deletion of the CPSase
domain allowed the expression of an ATCase totally insensi-
tive to UTP; thus UTP has no inhibitory e¡ect on the ATC-
ase activity when the whole GATase-CPSase domain is ab-
sent. Two sets of experiments support the idea that the
intermediary DHOase-like region does not hold the UTP reg-
ulatory site : (i) none of the FUR2 mutations located by Ja-
quet [5] was found to be localized in this region; (ii) prelimi-
nary studies on an Ura2 protein truncated of its DHOase-like
region have shown that this protein exhibited both activities,
but CPSase ^ whose speci¢c activity was low ^ responded to
UTP inhibition while ATCase was totally insensitive to UTP
(data not shown). All these results led us to the conclusion
that only one UTP binding site exists which is located on the
CPSase domain.
These results also point to the importance of the association
between domains in the regulation of both activities by UTP.
(a) The results obtained with truncated proteins show that
independent ATCase species (from pvCPS) are not sensitive
to UTP while CPSase species (pvATC) remain sensitive to the
inhibitor. CPSase activity can thus be inhibited independently
of ATCase, probably through conformational changes inside
the isolated CPSase domain, as suggested by the hyperbolic
decrease of this CPSase activity when UTP concentrations
increase.
(b) The results obtained with the Ura2-GFP fusion protein
(from [p21]) have shown that the presence of the GFP at the
C-terminal end of the protein a¡ects neither CPSase nor
ATCase activities, even if the latter is known to be active as
a trimer. The GFP domain interferes with both enzyme re-
sponses to UTP: it a¡ects ATCase sensitivity to UTP which is
dramatically reduced while CPSase remains sensitive to higher
concentrations of UTP. However, the sigmoidal kinetics of
inhibition of CPSase could re£ect a possible cooperativity
between sites on which UTP binds (thus CPSase domains),
a conclusion which cannot be drawn from CPSase-[pvATC]
data which support no cooperativity.
Thus, taking into account the signi¢cant di¡erences which
appear between the mechanisms involved in the speci¢c inhib-
ition of ATCase or CPSase activities, we suggest the following
model.
On the one hand CPSase, always found to be ^ more or less
^ sensitive to UTP, even in the absence of the ATCase domain
(Ura2vATC), would be covalently linked to the UTP binding
site; its inhibition would be induced by conformational
changes associated, or not, with a cooperative ¢xation of
UTP on its regulatory site(s) ; on the other hand, ATCase
sensitivity to UTP ^ as observed with modi¢ed Ura2 proteins
(Ura2-GFP, Ura2-vCPS or Ura2-vDHO) ^ would only be
regulated through non-covalent (weak) interactions with the
CPSase domain holding the UTP regulatory site. Previous
observations, made on the native Ura2 protein, can also
take place within this model: an ATCase species no longer
sensitive to UTP has already been found when dissociation of
the native Ura2 protein (carrying both activities sensible to
UTP) occurred, either on sucrose density gradients [10] or
upon its heat denaturation [18,19], while in both cases,
CPSase species still remained sensitive to UTP inhibition [18].
Structural analyses have suggested that a de¢ned area on
the ATCase domain could be involved in interactions: struc-
tural properties of the ATCase catalytic domain from CAD
[20] and from Ura2 [21] have been deduced from E. coli ATC-
ase crystallographic data [21^23]. Both sequences were in
agreement with a trimeric structure for the ATCase catalytic
domain, the active site(s) being located at the interface be-
tween two monomers. The amino acids known to be involved
in interactions with regulatory subunits of E. coli ATCase
were not found on the eukaryotic sequences, but new hydro-
phobic residues ^ absent on E. coli ATCase trimer ^ appeared
on the surface of the eukaryotic trimers, on the other side of
the catalytic sites. The authors suggested that this surface
could be involved in interactions with another protein or
with another domain of the same protein [21]. Some FUR2
mutations which have been described are actually located on
this surface: this is the case for one group of Jaquet’s FUR2
point mutations whose location, when transferred on the
ATCase trimeric structure, maps in this area; another set of
Jacquet’s FUR2 mutations (which also induced a speci¢c loss
of ATCase inhibition) was localized on the second half of the
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CPSase domain [5]. The bipolar distribution of these FUR2
mutations strongly supports the idea that interactions between
ATCase and CPSase domains would be responsible for
ATCase feedback inhibition.
Similar conclusions were obtained with the fusion protein
whose GFP domain (fused to the terminal residue of the Ura2
sequence known to emerge on the trimer surface opposite the
catalytic site) most probably points out on this surface, im-
pairing its normal interactions. Thus, UTP inhibition of ATC-
ase activity is likely to involve interactions between the ATC-
ase trimer surface opposite the catalytic site and the second
half of the CPSase domain which carries the UTP binding
site.
Interactions have also been proposed to explain a mecha-
nism which di¡ers from those involved in inhibition by UTP,
but which takes place in the yeast Ura2 [24] as well as in the
mammalian CAD [25] multifunctional proteins: channeling of
CP between the CPSase and ATCase domains. Speci¢c inter-
actions proposed to be involved in this mechanism should
allow alignment of catalytic domains in order to facilitate
the transfer of CP from one catalytic site to the other [25].
Residues involved in such interactions should thus be on the
catalytic side of the ATCase trimer, unlike those proposed to
be involved into UTP inhibition. Studies carried out on the
yeast Ura2 protein suggested that channeling occurs between
domains carried by the same polypeptide chain [24]. Work is
in progress to investigate whether ATCase feedback inhibition
would, or would not, require such a speci¢c contribution of
the Ura2 polypeptide chains.
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